Steven, Philipp, Braun, Tobias, Kroesser, Sonja and Gehlsen, Uta ORCID: 0000-0001-9057-9199 (2017). Influence of Aging on Severity and Anti-Inflammatory Treatment of Experimental Dry Eye Disease. Klinische Monatsblat. Augenheilkunde, 234 (5). S. 662 - 670. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-3999

Full text not available from this repository.

Abstract

Purpose Aging is an important factor in dry-eye disease that has not been studied in the context of therapeutic measures. Aging-associated modifications of the ocular immune system implicate that anti-inflammatory therapiesmay act differently among younger individuals in terms of onset and effect of different substances. The goal of this study was to determine differences in clinical phenotype and topical anti-inflammatory therapy using a desiccating stress mouse model. Methods An experimental dry-eye disease (desiccating stress model) was induced in 12-week and 12-month-old female BALB/c mice. Topical therapy included 0.05% cyclosporine/F4H5 (Novaliq), F4H5, 0.05% cyclosporine (Restasis (R), Allergan) and dexamethasone (Monodex (R), Thea Pharma) for 3 consecutive weeks. A control group received no therapy whatsoever. Readout parameters included tear secretion, corneal fluorescein staining at 5 timepoints and histological analysis of goblet cell count at the end of the experiments. Results The older mice demonstrated a significantly stronger dry eye phenotype than the younger mice. Following therapy, the older mice responded to topical anti-inflammatory therapy significantly later than the younger individuals. Regarding the different substances used, cyclosporine/F4H5 showed a significantly faster decrease in corneal fluoresceine staining after only 1 week of therapy in comparison to all other groups. This substance was also superior regarding tear secretion and goblet cell count in age matched groups and in comparison to younger mice. Conclusions These experimental data support the implication that aging should be considered as an important factor in daily clinical practice. Furthermore, the differences found between substance classes, such as calcineurin antagonists and steroids, as well as different drug formulations, should be considered in future pre-clinical and clinical trials.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Steven, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Braun, TobiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroesser, SonjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gehlsen, UtaUNSPECIFIEDorcid.org/0000-0001-9057-9199UNSPECIFIED
URN: urn:nbn:de:hbz:38-232056
DOI: 10.1055/s-0043-105137
Journal or Publication Title: Klinische Monatsblat. Augenheilkunde
Volume: 234
Number: 5
Page Range: S. 662 - 670
Date: 2017
Publisher: GEORG THIEME VERLAG KG
Place of Publication: STUTTGART
ISSN: 1439-3999
Language: German
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
AGE; KERATOCONJUNCTIVITIS; DYSFUNCTION; DEFICIENCYMultiple languages
OphthalmologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/23205

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item